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AbstrACt
Objectives To test whether the use of potentially 
inappropriate central nervous system acting medications, 
proton pump inhibitors (PPIs) or polypharmacy are 
associated with mortality in cognitively impaired older 
adults and whether frailer people are at greater risk of 
harm.
setting A cohort study nested within the Cognitive 
Function and Ageing Study II, a population representative 
cohort study of the older population in Cambridgeshire, 
Nottingham and Newcastle, UK.
Participants A total of 1154 cognitively impaired 
participants, aged 65 years or older.
Exposures Any use of antipsychotics, antidepressants, 
other anticholinergic medication, benzodiazepines or PPIs, 
polypharmacy (5–9) and hyperpolypharmacy (≥10 reported 
medications) were ascertained at baseline. Frailty was 
assessed using the Fried criteria.
Primary outcome Mortality up to 8 years follow-up. HRs 
associated with potentially inappropriate medication (PIM), 
frailty and their interaction were estimated adjusting for 
covariates.
results Within the sample, 44% were taking one or more 
PIM. Apart from antipsychotics (adjusted HR=3.24, 95% 
CI 1.83 to 5.73), use of specific PIM was not associated 
with greater subsequent mortality. Polypharmacy 
(HR=1.17, 95% CI 0.95 to 1.45) and hyperpolypharmacy 
were associated with mortality (HR=1.60, 95% CI 1.16 
to 2.22). Being frail (HR=1.90, 95% CI 1.32 to 2.72) or 
prefrail (HR=1.56, 95% CI 1.10 to 2.20) was associated 
with increased mortality. There was some evidence that 
the HR for polypharmacy on mortality was lower among 
frailer individuals, but the overall polypharmacy by frailty 
interaction was not statistically significant (p=0.102).
Conclusions For those with cognitive impairment, greater 
concern should be afforded to the number of medications 
than the prescription of specific classes. Frailer individuals 
may have a lower relative risk of mortality associated with 
polypharmacy than less frail individuals.
IntrOduCtIOn
More than 850 000 people live with dementia 
in the UK and many more have significant 
cognitive impairment.1 Around 70% of people 
with dementia live with comorbidity and are 
prescribed multiple medications.2 Polyphar-
macy, often defined as the regular use of 
five or more medications, is common among 
older adults and people with dementia, partic-
ularly as clinical prescribing guidelines often 
take a single disease focus, rarely accounting 
for patients with multimorbidity.3 
Polypharmacy has been associated with 
incident frailty.4 Frailty is often used to 
describe low physiological reserve and indi-
vidual susceptibility to stressors that may 
affect health5 6 and is an important deter-
minant of health outcomes in older people, 
including hospitalisation and mortality.7–9 
Incorporating frailty assessment into primary 
care is increasingly encouraged to iden-
tify individuals at greater risk of mortality, 
hospitalisation and susceptibility to adverse 
health outcomes.10 An important aspect of 
the validity of frailty measures is whether 
they can predict resilience or susceptibility to 
other potential risk factors.9 Recent findings 
strengths and limitations of this study
 ► This study followed a large population-representa-
tive cohort of people with cognitive impairment for 
up to 8 years.
 ► All medication use was included, both over-the-
counter and prescribed.
 ► Demographic-related and health-related confound-
ing variables were included in the analysis.
 ► There was no loss to follow-up as each participant 
was flagged for notification of mortality with the 
Office for National Statistics.
 ► Medication use and frailty were only ascertained 
once at baseline, ascertainment of medications re-
lied on self-report with interviewers checking pack-
aging and prescriptions where available.
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suggest that polypharmacy and frailty are associated 
with mortality, incident disability and hospitalisation 
compared with non-frail participants without polyphar-
macy.11 However, the moderating role of frailty in the rela-
tionship between polypharmacy and adverse outcomes, 
hence whether ‘frailty’ can be used to identify those at 
particular risk from polypharmacy, is unknown.
All medications have associated risks; a medication 
is considered a ‘potentially inappropriate medication’ 
(PIM) when the potential harm outweighs potential 
benefit among a particular group. PIMs are associated 
with increased risk of hospitalisation, mortality and other 
adverse health outcomes12–14 and around 29% of older 
people and 64% of people with dementia are prescribed 
at least one PIM.15 16 Validated criteria can be used to 
identify potentially inappropriate prescribing, examples 
include the Beers criteria, which is primarily used in 
the USA, and the European Screening Tool for Older 
Persons Prescribing (STOPP).17 18 These criteria identify 
PIM for specific patient groups, where interaction with 
specific diseases, prescriptions or overuse may result in 
adverse effects.
Proton pump inhibitors (PPIs) are considered poten-
tially inappropriate after 8 weeks in older adults according 
to STOPP criteria. PPIs are prescribed extensively and 
although generally considered safe and effective, recent 
evidence has linked PPIs with potential adverse events, 
including hip and spine fractures, community-acquired 
pneumonia, Clostridium difficile infections, and vitamin 
and mineral deficiencies.19–26 PPIs are considerable 
contributors to polypharmacy, with 27% of patients using 
PPIs being prescribed them long-term, despite long-
term effects being unknown.27 Understanding the long-
term effect of PPI use may improve patient safety, reduce 
unnecessary polypharmacy and have significant financial 
implications for health services.
The STOPP criteria also identify groups of PIM with 
central nervous system effects, and PIMs that are partic-
ularly inappropriate for people with dementia. People 
with dementia may be exposed to central nervous system 
acting medications, including antipsychotics, antidepres-
sants, benzodiazepines (BZDs) and medications with 
anticholinergic effects in order to treat comorbidities 
and manage behavioural and psychological symptoms. 
However, these medications are associated with adverse 
cardiovascular effects,28 hypotension, falls29–31 confusion, 
detrimental effects on cognition32 and mortality,33 and 
are considered potentially inappropriate in both STOPP 
and Beers criteria. People with dementia may be more 
susceptible to adverse effects of central nervous system 
acting medications due to age-related and disease-re-
lated pharmacokinetic and pharmacodynamic changes, 
including alterations in the blood–brain barrier permea-
bility associated with Alzheimer’s disease.34–36
Being frail may also increase susceptibility to adverse 
effects of PIM and polypharmacy, since frailty is defined 
as increased vulnerability to risk factors and lack of phys-
iological reserve.5 Using frailty criteria may, therefore, 
enable the identification of those at particular risk from 
PIM and polypharmacy, although whether frailty exacer-
bates any adverse effects of PIM is not known.
This study seeks to understand the effect of potentially 
inappropriate use of central nervous system acting drugs, 
PPIs and polypharmacy among cognitively impaired 
older adults, and whether any risk varies with increasing 
frailty. We used the Cognitive Function and Ageing Study 
II (CFAS II) to estimate (a) the association between PIMs 
and polypharmacy at baseline and survival up-to 8 years, 
and (b) the moderating role of frailty in this relationship.
MEthOds
 CFAS II is a cohort study of ageing in England. The design 
and methods have been described in detail elsewhere.37 In 
short, participants were randomly sampled from primary 
care lists within three geographic centres representing 
urban and rural areas (Nottingham, Cambridgeshire 
and Newcastle) between 2008 and 2011. In England, 
the vast majority of people are registered with a single 
primary care provider, and so primary care patient lists 
form sampling frames that are close to enumerations of 
the populations of specific areas. Approximately, 2500 
participants were recruited from each geographic area. 
All participants were aged 65 years or older at baseline 
and were interviewed in their usual place of residence, 
whether this was their own home or a long-term care 
facility, by a trained interviewer. The CFAS interview 
included questions on health and lifestyle, demographics, 
and current medication use, as well as a range of cogni-
tive tests and algorithmic dementia assessment. This was 
repeated at a two-year follow-up assessment.
sample
For the present study, we used data from all participants 
with a baseline Mini-Mental State Examination (MMSE) 
score of 24 or lower, indicating clinically significant cogni-
tive impairment.38 Participants were excluded if medica-
tion data were not recorded or were deemed unreliable, 
that is, if MMSE was less than 18 and proxy-reported 
medication data were unavailable.
Exposures
Medication use
Information on medication use was ascertained from the 
question: ‘Do you take any medicine, tablets or injec-
tions of any kind, that either you buy yourself or that are 
prescribed by your doctor?’ To improve data accuracy, 
reported medications were cross-checked with medica-
tion packs by the interviewer. In care homes, staff cross-
checked with medication lists. Medications were coded 
using Read Codes and Application Dictionary.39
Potentially inappropriate medications
PIMs were identified using STOPP criteria.18 We focused 
primarily on medications from Section D: Central Nervous 
System Criteria of STOPP, including antidepressants, 
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antipsychotics, other anticholinergics (ie, anticholiner-
gics other than antidepressants and antipsychotics) and 
BZDs. Acetylcholinesterase inhibitors, inappropriate in 
patients with vascular dementia, were not included in this 
study due to specific dementia subtype diagnosis informa-
tion being unavailable. PPIs, indicated as potentially inap-
propriate in long-term use, contributors to polypharmacy 
and a priority of deprescribing, were also included.19 40
Anticholinergic medications were defined using the 
anticholinergic cognitive burden scale (ACB). Medica-
tions with definite anticholinergic activity, classified as an 
ACB score of 3, were included.41 PIMs were then grouped 
into mutually exclusive categories of: (a) antipsychotic, 
(b) anticholinergic (excluding antipsychotics and anti-
depressants), (c) tricyclic antidepressants, (d) other 
antidepressants, (e) BZDs and (f) PPI (see online supple-
mentary appendix 1 containing medication code lists).
Polypharmacy
Total number of prescribed and over-the-counter medica-
tions was calculated from medication lists collated during 
interviews. This number excluded the specific PIM 
described above, to allow for mutually exclusive expo-
sures comparing PIM to polypharmacy and to understand 
the effect of polypharmacy on mortality, independent of 
specific PIM use. Polypharmacy was categorised as the 
use of between five and nine such medications, hyper-
polypharmacy as more than ten in line with previous 
studies.11 42
Time-varying exposure to PIM
To test the extent to which the exposure varied with 
time, the use of PIM at baseline and 2-year follow-up was 
compared, among the subsample for whom medication 
data were available at the 2-year follow-up interview.
Frailty
The frailty phenotype as first described by Fried et al5 was 
used to measure frailty. The frailty phenotype is known to 
predict adverse outcomes in a general older population.43 
This definition of frailty incorporates measures from 
multiple domains reflecting physiological decline and 
consists of five components: slowness, weakness, exhaus-
tion, weight loss and low physical activity. Individuals 
are deemed ‘frail’ if they are positive on three, four or 
five components, ‘prefrail’ if positive on one or two and 
‘not frail’ otherwise. We could not operationalise frailty 
exactly as originally performed in the Cardiovascular 
Health Study,5 but in common with other epidemiolog-
ical studies of ageing44 45 each component was operation-
alised as closely as possible using available data, as follows:
Slowness was measured using the average walking speed 
from two gait speed tests across 2.4 metres. Participants 
falling within the slowest quartile of the whole CFAS II 
sample were considered impaired for this component. 
Participants who did not consent or could not complete 
the test were also considered impaired.
Weakness was assessed using the timed sit-to-stand 
test.46 Participants were asked to stand from sitting five 
times, without using their arms. Participants who did not 
consent, could not complete the test and those within the 
slowest quartile of time among completers were consid-
ered impaired.
Exhaustion was self-reported in answer to the question 
‘Do you get worn out/exhausted towards the evening?’ 
If there was no response, interviewer rating of observed 
slow movements not due to physical illness was used. 
Both questions were measured with three response cate-
gories (no/mild/severe). Participants with mild or severe 
exhaustion, not explained by strenuous activities, were 
coded as frail on this criterion.
Weight loss was assessed by self-report. Participants 
reporting losing 10 lbs (4.5 kg) or more in ≤6 months 
prior to the interview were classified as positive on this 
criterion.
Low physical activity was assessed through self-reported 
time spent doing vigorous, moderate or mildly energetic 
activities. This was scored based on responses to a series of 
questions about time spent in specific activities, including, 
for example, swimming, jogging, walking, gardening and 
housework (see online supplementary appendix 2 for 
a full list). A score of 1 was allocated for each activity if 
a participant reported doing an activity hardly ever or 
never, less than three times a month or not engaging in 
the activity at all, and 0 if more frequently. The scores 
across activities were summed to create a continuous vari-
able, where higher scores indicated less activity. Partici-
pants in the least active quartile were coded positive on 
this criterion.
Other covariates
Multivariate analyses were adjusted for age, sex, living 
situation (care home, residential homes, nursing homes 
and long-stay hospitals, or own home), cognitive impair-
ment (MMSE score) and number of self-reported 
comorbidities (angina, arthritis, asthma, cancer, chronic 
bronchitis, depression, diabetes, epilepsy, heart attack, 
high blood pressure, intermittent claudication, low blood 
pressure, Parkinson’s disease, peptic ulcers, pernicious 
anaemia and stroke).
Outcomes
CFAS II participants were flagged on the UK Office 
for National Statistics National Health Service Central 
Register for notification of date of death, and so survival 
status is known for all participants. The current analysis 
includes all deaths up to 31 October 2016, providing up 
to 8 years follow-up.
statistical analysis
Univariate analysis
Kaplan-Meier curves estimated survival probabilities from 
baseline until censoring or death. Logrank tests were used 
to test survival differences between users and non-users 
of each PIM. Participants reporting polypharmacy and 
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hyperpolypharmacy were compared with those reporting 
zero to four medications.
Cox regression models estimated univariate HRs (95% 
CIs) for each exposure. Participants entered the analysis 
at the time of baseline interview, and were followed until 
death or censoring on 31st October 2016. Time since 
the interview was the time scale for all analyses.
Multivariate analysis
Two Cox proportional hazards regression models esti-
mated independent effects of each PIM and polyphar-
macy, controlling for covariates. Model 1 adjusted for age, 
sex, cognitive impairment, living situation and comor-
bidities. Model 2 included a categorical frailty variable 
(non-frail, prefrail and frail). Sensitivity analyses included 
adding individual frailty components in Cox multivar-
iate regressions to assess their association with mortality, 
and adjusting for each comorbid condition individually 
rather than as a single cumulative variable. The propor-
tional hazards assumption was tested by inspection of 
Schoenfeld residuals.47
Frailty as a moderator
First, multivariate analyses as described above were strati-
fied by baseline frailty status. Interaction terms were then 
added to the full model to test the moderating effect of 
frailty on the link between each PIM, polypharmacy and 
mortality. Likelihood-ratio tests assessed the statistical 
significance of PIM by frailty and polypharmacy by frailty 
interactions.
The data set analysed during the current study was 
provided by the CFAS. Details of how to request CFAS 
data are available  (http://www. cfas. ac. uk/ cfas- ii/ cfasii- 
data/). All analyses were performed using Stata V.14.
rEsults
Of the 7762 CFAS II participants, 1154 met inclusion 
criteria (see figure 1). Within the final sample, 62% 
were female, mean age was 79 years (SD=7.4) and 154 
(13%) had a study diagnosis of dementia (see table 1). 
Participants reported a mean average of 2.4 (SD=1.6) 
comorbidities, 5.5 (SD=3.6) regular medications and 
44% reported taking at least one PIM. PPIs were most 
frequent (n=331, 28.7%), followed by ‘other antidepres-
sants’ (n=119, 10.3%), ‘tricyclic antidepressants’ (n=76, 
6.6%), anticholinergics (n=71, 6.2%), BZDs (n=46, 4.0%) 
and antipsychotics (n=21, 1.8%). There were 493 (42.7%) 
participants taking 5–9 medications (polypharmacy) and 
110 (9.5%) taking ≥10 medications, excluding PIMs.
survival analyses
Univariate analyses
Up to 31 October 2016, 489 (42.4%) participants had 
died; the median follow-up time was 5.6 years. Among 
participants reporting PIM, 73% (n=11) of antipsychotic 
users, 52% (n=37) of users of other anticholinergics, 43% 
(n=33) of users of tricyclic antidepressants, 46% (n=21) 
of BZD users, 46% (n=55) of other antidepressant users 
and 44% (n=145) of PPI users had died. Of participants 
taking 5–9 and ≥10 medications, 47% (n=233) and 55% 
(n=60) had died.
Kaplan-Meier survival curves suggested a difference in 
survival in participants with polypharmacy and hyperpoly-
pharmacy and users of antipsychotics, but not in users 
of the others PIMs compared to non-users (figure 2). A 
statistically significant difference in survival was seen in 
users of antipsychotics compared to non-users, in logrank 
test (χ2=8.21, df=1, p≤0.01) and unadjusted Cox regres-
sion models (HR=2.19, 95% CI 1.26 to 3.81). No signif-
icant effect on survival was seen for any other central 
nervous system acting PIM (table 2) and there was no 
significant effect on survival associated with PPI use 
(HR=1.16, 95% CI 0.95 to 1.42). Statistically significant 
Figure 1 Participant inclusion from CFAS II for 
analysis. aUnreliable medication data includes MMSE 
score≤18 or missing and no proxy to answer medications 
question. CFAS II, Cognitive Function and Ageing Study 
II; MMSE, Mini-Mental State Examination. 
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difference in survival was seen across polypharmacy cate-
gories (χ2=23.15, df=2, p≤0.01). Polypharmacy and hyper-
polypharmacy were both significantly associated with 
mortality, HR=1.39 (95% CI 1.14 to 1.70) and HR=1.95 
(95% CI 1.45 to 2.61), respectively (see table 2).
Multivariable analyses
The association between antipsychotics and mortality 
remained after adjusting for demographic variables, 
comorbidities and cognitive impairment (HR=3.24, 
95% CI 1.83 to 5.73) and after adjusting for frailty. After 
adjusting for confounders, no significant association 
with mortality was evident in the other central nervous 
system acting PIM or PPIs (see table 2). Adjustment for 
confounders explained about half of the univariable 
effect of polypharmacy such that it was no longer statis-
tically significant (multivariate model HR=1.21, 95% CI 
0.97 to 1.50); however, hyperpolypharmacy remained 
significantly associated with mortality in both adjusted 
models (frailty model: HR=1.60, 95% CI 1.16 to 2.22) (see 
table 2). The proportional hazards assumption, assessed 
using Schoenfeld residuals, was not violated in this mode
l (χ2=16.91, df=15, p=0.324). There was no substantial 
change in estimates when comorbid conditions were 
included individually in the main multivariate model (see 
online supplementary file appendix 3).
Continuation of medication use
At the 2-year follow-up, 561 (48.6%) had survived and 
provided medication data. Among these, 69% (n=29) of 
Table 1 Sample characteristics by frailty classification. Cognitive Function and Ageing Study II
Characteristics
Total sample 
n=1154
Characteristics within frailty classifications
Non-frail
n=204
Prefrail
n=530
Frail
n=420
Gender (% female) 717 (62.1) 96 (47.1) 314 (59.3) 307 (73.1)
Mean age (years, SD) 78.8 (7.4) 75.7 (6.5) 78.8 (7.4) 80.4 (7.3)
PIMs (count, %)
  Antipsychotics 21 (1.8) 4 (2.0) 7 (1.3) 10 (2.4)
  Anticholinergics 78 (6.8) 6 (2.9) 36 (6.8) 36 (8.6)
  Tricyclic antidepressants 76 (6.6) 5 (2.5) 30 (5.6) 41 (9.8)
  Other antidepressants 119 (10.3) 14 (6.9) 35 (6.6) 70 (16.7)
  Benzodiazepines 46 (4.0) 4 (2.0) 14 (2.6) 28 (6.7)
  Proton pump inhibitors 331 (28.7) 34 (16.7) 149 (28.1) 148 (35.2)
Polypharmacy
  0–4 551 (47.8) 143 (70.1) 260 (49.1) 148 (35.2)
  5–9 493 (42.7) 56 (27.5) 229 (43.2) 208 (49.5)
  10+ 110 (9.5) 5 (2.5) 41 (7.7) 64 (15.2)
Cognitive impairment
  Dementia (count, %) 154 (13.3) 16 (7.8) 79 (14.9) 59 (14.1)
  MMSE score (count, %)
   22–24 789 (68.4) 164 (80.4) 362 (68.3) 263 (62.6)
   21–19 283 (24.5) 37 (18.1) 127 (24.0) 119 (28.3)
   ≤18 82 (7.1) 3 (1.5) 41 (7.7) 38 (9.1)
  Number of comorbidities (mean, SD) 2.4 (1.6) 1.6 (1.2) 2.3 (1.5) 2.9 (1.7)
  Care home resident (count, %) 47 (4.1) 2 (1.0) 22 (4.2) 23 (5.5)
Frailty individual components (count, %)
  Low physical activity 313 (27.1) – 58 (10.9) 255 (60.7)
  Weight loss 122 (10.6) – 29 (5.5) 93 (22.1)
  Weakness* 802 (69.5) – 388 (73.2) 414 (98.6)
  Slowness† 702 (60.8) – 313 (59.1) 389 (92.6)
  Exhaustion 334 (28.9) – 74 (14.0) 260 (61.9)
  Death before 31 October 2016 (count, %) 489 (42.4) 45 (22.1) 226 (42.6) 218 (51.9)
*Missing n=603: categorised as frail if missing due to inability to complete the test.
†Missing n=244: categorised as frail if missing due to inability to complete the test.
MMSE, Mini-Mental State Examination score; PIMs, potentially inappropriate medications.  on
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those reporting anticholinergics at baseline also reported 
anticholinergics at 2 years, 60% (n=3) continued anti-
psychotics, 59% (n=13) continued BZDs, 77% (n=31) 
continued tricyclics and 85% (n=136) of those using PPI 
at baseline were also using PPI at follow-up. This suggests 
that the majority of medication use reported at baseline 
reflected relatively long-term use.
Frailty
At baseline, 36.4% of the sample were classified as frail 
(n=420), while 45.9% were prefrail (n=530). PIM use was 
less frequently reported among the non-frail (17.7%) 
group compared with prefrail (27.7%) and frail (32.1%) 
participants. At the point of censoring, 22.1% (n=45) of 
non-frail, 42.6% (n=226) prefrail and 51.9% (n=218) of 
frail participants had died.
In univariate analyses, prefrail or frail participants were 
at a significantly increased risk of mortality compared with 
non-frail (prefrail: HR=2.22, 95% CI 1.59 to 3.09; frail: 
HR=2.92, 95% CI 2.09 to 4.07). Being frail and prefrail 
remained significantly associated with mortality in the 
fully adjusted model (frail: HR=1.90, 95% CI 1.32 to 2.71; 
prefrail: HR=1.56, 95% CI 1.11 to 2.20) (see table 2).
Frailty as moderator of the effect of PIM and polypharmacy
Stratifying multivariate models by frailty status suggested 
similar relative risk of mortality among antipsychotic 
users at all levels of frailty. The HR associated with antipsy-
chotic use among non-frail users was 3.60 (95% CI 0.40 
to 31.99), was 2.89 (95% CI 1.26 to 6.66) in prefrail and 
was 3.34 (95% CI 1.37 to 8.12) in frail antipsychotic users 
(table 3).
Frailty and polypharmacy interaction terms suggested 
worse mortality associated with polypharmacy and hyper-
polypharmacy in people who were not frail compared 
with those who were prefrail or frail (table 3). However, 
this interaction was not statistically significant (likeli-
hood-ratio test for interaction: χ2=7.73, df=4, p=0.102).
The association between BZDs and mortality signifi-
cantly varied across frailty groups, (likelihood-ratio test 
for interaction: χ2=6.05, df=2, p=0.049) and suggested 
an inverse relationship between BZD use and mortality 
among the frail (HR=0.43), but no effect among the 
prefrail or not frail participants (table 3).
Estimating the effect of individual frailty components
Including frailty components individually in adjusted anal-
ysis instead of the composite measure made little differ-
ence to HRs estimated from previous models. As individual 
markers of frailty, low physical activity, weakness (measured 
by chair-rise test) and slowness (measured by the gait-
speed test) were individually associated with mortality (low 
physical activity: HR=1.41, 95% CI 1.15 to 1.71; weakness: 
HR=2.23, 95% CI 1.77 to 2.83 and slowness: HR=1.99, 95% 
CI 1.62 to 2.45). However, slow gait was the only compo-
nent independently associated with mortality in the multi-
variate model (HR=1.42, 95% CI 1.12 to 1.81) (table 4).
Figure 2 Kaplan-Meir survival curves showing the proportion of patients surviving with time, stratified by baseline use of 
PIM. (A) Shows the effect of antipsychotics, (B) the effect of anticholinergics apart from antipsychotics and antidepressants, 
(C) the effect of tricyclics, (D) other antidepressants, (E) benzodiazepines and (F) the total number of other drugs coded as 
polypharmacy (5–9 drugs) or hyperpolypharmacy (10 or more) excluding any of the categories previously described. PIM, 
potentially inappropriate medication.
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dIsCussIOn
This study estimated the association between PIMs, 
polypharmacy and risk of mortality among cognitively 
impaired older adults and the moderating role of frailty in 
this relationship. We found that, as expected, use of anti-
psychotic medications, polypharmacy and hyperpolyphar-
macy were associated with an increased risk of mortality, 
but no other specific PIM we tested was linked to the risk 
of death. The excess risk associated with hyperpolyphar-
macy and with antipsychotics remained after adjustment 
for frailty status. Polypharmacy was more common among 
frailer participants. Contrary to expectation, the HR for 
death associated with polypharmacy appeared higher 
among the non-frail population than among the prefrail 
or frail, with excess risk of death associated with using five 
to nine medications seeming almost exclusively restricted 
to the least physically frail. The frailty phenotype did 
independently predict mortality, but when analysed indi-
vidually slow gait speed was the only component of the 
frailty measure that independently predicted mortality in 
this cohort.
The link between antipsychotic medication and 
mortality in people with dementia is well known48 and 
our result extends this finding to a broader group with 
cognitive impairment. Previous studies have also found 
an increased risk of death associated with increased anti-
cholinergic burden.33 Since anticholinergic medications 
encompasses a wide variety of medications, including 
many antidepressants and antipsychotics, in this analysis, 
anticholinergics were subclassified into mutually exclu-
sive categories to understand the contribution of specific 
medication classes. Our finding that only antipsychotic 
medications were associated with increased mortality, 
compared with tricyclic antidepressants or other anticho-
linergic medications, indicates a potential class-specific 
effect, such that antipsychotic use may be the driver of 
previously observed associations between anticholiner-
gics and mortality when anticholinergics are considered 
together.49 Hence, as previously suggested elsewhere,50 
considering ‘anticholinergics’ as a class with respect to 
adverse outcomes might not be meaningful.
We found no evidence for an association between PPI 
use and mortality in this cognitively impaired population. 
PPIs are highly prevalent and are often overused without 
appropriate indication.27 51 52 For people with comorbid-
ities and polypharmacy, who are taking PPIs on a long-
term and potentially inappropriate basis, there may also 
be a risk of drug–drug interactions, which can lead to 
Table 2 Unadjusted and adjusted potentially inappropriate medication (PIM) use HRs for survival, univariate and multivariate 
models. Cognitive Function and Ageing Study II n=1154
Variables Univariate Multivariate Frailty model†
PIM
  Antipsychotics 2.19* (1.26 to 3.81) 3.24* (1.83 to 5.73) 3.28* (1.85 to 5.80)
  Tricyclic antidepressants 1.01 (0.70 to 1.47) 1.11 (0.76 to 1.63) 1.06 (0.72 to 1.55)
  Anticholinergics 1.29 (0.92 to 1.80) 1.18 (0.83 to 1.67) 1.17 (0.83 to 1.66)
  Other antidepressants 1.21 (0.91 to 1.61) 0.94 (0.70 to 1.28) 0.90 (0.66 to 1.22)
  Benzodiazepines 1.08 (0.67 to 1.72) 0.75 (0.47 to 1.21) 0.72 (0.45 to 1.16)
  Proton pump inhibitor 1.16 (0.95 to 1.42) 1.08 (0.88 to 1.33) 1.05 (0.86 to 1.30)
Polypharmacy
  0–4 1 1 1
  5–9 1.39* (1.14 to 1.70) 1.21 (0.97 to 1.50) 1.17 (0.95 to 1.45)
  10+ 1.95* (1.45 to 2.61) 1.72* (1.24 to 2.38) 1.60* (1.16 to 2.22)
Covariates
  Age at interview (per year) 1.10* (1.09 to 1.12) 1.10* (1.09 to 1.12) 1.10* (1.08 to 1.12)
  Gender (female) 0.76* (0.63 to 0.91) 0.62* (0.51 to 0.75) 0.57* (0.46 to 0.69)
  MMSE score (per point) 0.88* (0.85 to 0.90) 0.91* (0.88 to 0.94) 0.91* (0.89 to 0.94)
  Care home residence 2.36* (1.63 to 3.42) 1.23 (0.83 to 1.84) 1.20 (0.81 to 1.80)
  Comorbidities 1.06* (1.00 to 1.13) 1.08* (1.01 to 1.15) 1.05 (0.98 to 1.13)
Frailty
  Prefrail 2.22* (1.59 to 3.09) 1.56* (1.11 to 2.20)
  Frail 2.92* (2.09 to 4.07) 1.90* (1.32 to 2.72)
HR (95% CI).
*P<0.05. 
†Multivariate model adjusted for frailty.
MMSE, Mini-Mental State Examination score (0–30 with higher scores indicating better cognition).
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a range of adverse effects. Deprescribing inappropriate 
PPIs among older people is considered a priority40 and 
while we did not find PPI use was associated with survival, 
there is building evidence suggesting PPIs are associated 
with other clinically important adverse effects including 
C. difficile and increased risk of fractures.27 53
In this novel investigation of the role of frailty on the 
effect of PIM in older adults with cognitive impairment, we 
found some evidence of a moderating role in that the HR 
for polypharmacy was higher among the least physically 
frail individuals. This may be partly caused by a lower risk 
of death from other causes among the less frail groups, so 
that if polypharmacy caused a similar increase in absolute 
risk of mortality across groups, this would correspond to a 
lower relative risk among the frailer participants.
BZD use was associated with better survival in frail partic-
ipants. Long-term use of BZDs is discouraged; however, 
more than two-thirds of our participants using BZD at 
baseline were still using BZD 2 years later, suggesting that 
much of the BZD use recorded in our study is long-term. 
It is possible that prescribing behaviours around BZDs 
may differ compared with other PIMs. This could include 
improved monitoring of efficacy and safety leading to 
subsequent apparent protective effects. Alternatively, this 
finding might represent residual confounding such that 
BZDs are prescribed to those with a lower risk of death, 
an effect of BZDs causing otherwise healthy people to be 
classified as frail, or it is possible that this is a chance asso-
ciation given the large numbers of individual hypotheses 
being tested and borderline statistical significance of the 
interaction effect. In any case, there is no evidence from 
this study that BZDs or other individual PIM apart from 
antipsychotics are associated with excess mortality among 
people with cognitive impairment.
Previous studies have described that polypharmacy and 
hyperpolypharmacy are associated with frailty4 and that 
frailty and polypharmacy are associated with mortality, 
incident disability and hospitalisation.11 42 While including 
frailty and polypharmacy interactions in our analysis did 
indicate a significantly increased risk of mortality in frail, 
hyperpolypharmacy participants, the greatest risk was 
observed in non-frail participants with polypharmacy. 
This interaction effect was not statistically significant in 
our study; however, a cohort study of men aged 70 years 
and older characterised transitions across frailty states and 
death and similarly found that additional medications 
Table 3 HRs estimated by Cox regression models for association between potentially inappropriate medication (PIM) use and 
mortality, adjusted for age, gender, MMSE score, care home residence and comorbidities and stratified by frailty. Data from the 
Cognitive Function and Ageing Study II
Variables
Cox regression analysis stratified by frailty classification† 
Likelihood ratio‡ 
χ2 (p value)
Not frail
n=204
Prefrail
n=530
Frail
n=420
PIM
  Antipsychotic 3.60 (0.40 to 31.99) 2.89* (1.26 to 6.66) 3.34* (1.37 to 8.12) 0.01 (0.995)
  Tricyclic antidepressant 0 1.84 (0.98 to 3.44) 0.90 (0.55 to 1.48) 5.63 (0.060)
  Anticholinergics 1.29 (0.16 to 10.61) 1.05 (0.61 to 1.79) 1.23 (0.76 to 2.01) 0.32 (0.854)
  Other antidepressants 0.86 (0.23 to 3.20) 1.12 (0.67 to 1.89) 0.74 (0.49 to 1.12) 2.93 (0.230)
  Benzodiazepines 0.92 (0.11 to 7.78) 1.40 (0.66 to 2.97) 0.43* (0.21 to 0.86) 6.05 (0.049)*
  Proton pump inhibitor 1.05 (0.43 to 2.59) 1.04 (0.76 to 1.42) 1.09 (0.80 to 1.49) 0.43 (0.808)
Polypharmacy
  0–4 1 1 1 7.73
  5–9 2.34* (1.16 to 4.70) 1.07 (0.78 to 1.45) 1.17 (0.84 to 1.64) (0.102)
  10+ 4.22 (0.90 to 19.90) 1.31 (0.75 to 2.29) 1.80* (1.15 to 2.82)
Covariates
  Age at interview 1.13* (1.07 to 1.19) 1.11* (1.09 to 1.13) 1.08* (1.06 to 1.11)
  Gender (female) 0.71 (0.35 to 1.43) 0.67* (0.50 to 0.89) 0.43* (0.31 to 0.58)
  MMSE score (per point) 0.87* (0.77 to 0.98) 0.92* (0.88 to 0.96) 0.91* (0.87 to 0.96)
  Care home residence 0.00 0.92 (0.50 to 1.71) 1.68 (0.98 to 2.88)
  Comorbidities 1.16 (0.90 to 1.50) 1.03 (0.93 to 1.14) 1.02 (0.92 to 1.12)
HR (95% CI).
*P<0.05.
†Classified as positive on individual frailty components if score, rating or time within the upper quartile. Classified as frail if positive on 3–5 
individual frailty components and prefrail if 1–2 components.
‡Likelihood ratio test comparing exposure–frailty interaction models with multivariate frailty model with prefrail group as baseline.
MMSE, Mini-Mental State Examination score (0–30 with higher scores indicating better cognition). 
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were associated with increased risk of mortality from 
non-frail state but not from prefrail or frail state.54
strengths and limitations of the study
Our results were drawn from a large, nationally repre-
sentative, population-based cohort study with data on 
both prescribed and over-the-counter medications. 
The strength of this analysis lies in the mutually exclu-
sive categorisation of exposures, including polypharmacy 
that excluded individual PIM exposure, since the proba-
bility of PIM exposure is a function of the total number 
of medications. However, we did not consider medication 
dose or duration of use. Although we did not directly 
incorporate varying medication exposure as only a subset 
of participants underwent a single second assessment at 
2 years, we did find that the exposure was typically long-
term as the majority of participants who reported each 
PIM use at baseline, also reported the same PIM at 2-year 
follow-up. This suggests that much PIM use recorded in 
our study was ‘prevalent use’, reflecting long-term use 
among a population who are stable on each medication, 
and so might not be applicable to those considering a 
new prescription of a PIM and who may be expected to 
be at higher initial risk.
We could not operationalise phenotypic frailty measures 
exactly as per their original definition,5 although our 
frailty measure did independently predict mortality in 
this sample and our approach to measuring frailty using 
existing data is similar to that taken by many other epide-
miological studies.
Finally, although the analysis adjusted for multiple 
covariates, the possibility of residual confounding 
remains. In particular, we could not control for every 
possible indication for medications contributing to poly-
pharmacy owing to the limitations of the available data. 
For example, CFAS II did not record data on chronic 
kidney disease or heart failure that are also linked to 
medication use and mortality. However, controlling for 
the frailty variables, which reflect general health status, 
did not attenuate the associations between polypharmacy 
and death.
Implications
There are few prescribing guidelines addressing the 
specific needs of patients living with dementia and multi-
morbidity, the findings from this study will assist in under-
standing the safety of medicines in this population. Given 
these findings, consideration of the number of medica-
tions used rather than individual PIM (with the excep-
tion of antipsychotics) may be more important among 
cognitively impaired older adults. With respect to anti-
psychotics, deprescribing guidelines for behavioural and 
psychological symptoms of dementia have been devel-
oped and could help in reducing the harm associated 
with inappropriate prescribing.22
Implications for the measurement and clinical application of 
frailty measures
This study used a widely applied physical phenotypic 
definition of frailty.5 However, this definition does not 
account for cognitive, psychological and social frailty 
components, potentially resulting in underestimation of 
frailty in a cognitively impaired sample.55 There are no 
single established means of defining frailty but including 
frailty assessment in clinical practice is increasing.10 Slow 
gait speed was the only frailty marker independently asso-
ciated with mortality in this study, suggesting this alone 
may provide as useful an assessment of frailty as the full 
phenotypic measure in this group. A valid, feasible and 
reliable frailty assessment is needed and important for 
identifying vulnerable individuals, applying evidence-
based interventions and comparing or predicting health 
outcomes within this growing older population.
Frailty itself has been shown to be a strong predictor of 
adverse outcomes but this effect may differ with varying 
levels polypharmacy.56 Frailty as applied in our study did 
not identify those at most risk of the adverse effects of 
PIM. That the interaction between polypharmacy and 
frailty was of the opposite direction to that expected, with 
Table 4 Risk of mortality associated with the use of 
PIM and individual frailty components in univariate and 
multivariate models. Cognitive Function and Ageing Study 
II n=1154
Variables
Univariate
HR (95% CI)
Multivariate†
HR (95% CI)
Antipsychotic 2.19* (1.26 to 3.81) 3.30* (1.86 to 5.86)
Tricyclic 
antidepressant
1.01 (0.70 to 1.47) 1.04 (0.71 to 1.53)
Anticholinergic 1.29 (0.92 to 1.80) 1.17 (0.83 to 1.66)
Other 
antidepressants
1.21 (0.91 to 1.61) 0.88 (0.65 to 1.20)
Benzodiazepines 1.08 (0.67 to 1.72) 0.73 (0.46 to 1.18)
PPI 1.16 (0.95 to 1.42) 1.05 (0.85 to 1.29)
Polypharmacy
  0–4 1 1
  5–9 1.39* (1.14 to 1.70) 1.17 (0.95 to 1.46)
  10+ 1.95* (1.45 to 2.61) 1.65 (1.19 to 2.29)
Frailty components
  Low physical 
activity
1.41* (1.15 to 1.71) 1.22 (0.98 to 1.51)
  Weight loss 1.25 (0.94 to 1.66) 1.19 (0.89 to 1.60)
  Weakness 2.23* (1.77 to 2.83) 1.13 (0.86 to 1.49)
  Slowness 1.99* (1.62 to 2.45) 1.42* (1.12 to 1.81)
  Exhaustion 1.10 (0.90 to 1.35) 0.98 (0.79 to 1.22)
*P<0.05.
†Adjusted for age, sex, MMSE, care home residence and 
comorbidities (heart attack, diabetes mellitus, bronchitis, 
stroke, arthritis, asthma, angina pectoris, hypertension, 
epilepsy, thyroid problems, Parkinson’s disease, pernicious 
anaemia and depression).
MMSE, Mini-Mental State Examination; PIM, potentially 
inappropriate medication; PPI, proton pump inhibitor. 
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the least frail at highest relative risk calls into question the 
concept of frailty as reflecting susceptibility to other risks; 
this should be more rigorously tested in future studies.
To conclude, in this analysis of a large, nationally repre-
sentative cognitively impaired sample, we found that with 
the exception of antipsychotics, potentially inappropriate 
central nervous system acting medications were not indi-
vidually associated with mortality. Polypharmacy and 
hyperpolypharmacy were associated with an increased 
risk of mortality indicating that managing the number of 
medications used remains a priority, particularly in cogni-
tively impaired older adults, irrespective of physical frailty.
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